Abstract Body

Background: Oxidized lipids play key roles in both viral replication and T cell biology and oxidized lipoproteins may directly affect adaptive immunity. High density lipoprotein (HDL) has many functions including the disposal of oxidized lipids. However, in systemic inflammatory states, it can become oxidized (HDLox) and dysfunctional. To examine effects of oxidized HDL that may potentiate HIV-1 replication and further drive immune activation we evaluated the in vitro effects of HDLox on the antiviral activity of HIV-1-specific CD8+ T-cells (CTLs). Methodology: Pooled HDL from healthy subjects was oxidized in vitro using 13(S)-hydroperoxy-9Z, 11E-octadecadienoic acid (13(S)-HPODE), an in vivo generated potent lipid oxidant that has previously been shown to modify HDL in vivo and make it dysfunctional. T1 cells were infected with HIV-1 NL4-3.1 at low multiplicity and cultured with or without HIV-1 specific CTLs (Figure) in the presence of normal HDL or HDLox (50-100 ug/ml). Viral replication was assessed by p24 ELISA. At six days after infection virus suppression was quantified by using a virus suppression assay and was calculated as: “Suppression” = (Log10 pg/ml p24 antigen without CTL) – (Log10 pg/ml p24 antigen with CTL) and Virus Suppression Efficiency as: “Suppression Efficiency”= “Suppression” ÷ (Log10 pg/ml p24 antigen without CTL). Paired T-test was used for comparison of values between pairs. Results: A representative experiment from a Gag-specific CTL clone is shown in Figure 1A. HIV-1-specific CTLs reduced Log10 pg/ml p24 antigen and suppressed virus replication but HDLox reduced the suppression efficiency of HIV-1-specific CTLs in a dose-dependent way (Figure). Conclusions: Dysfunctional (oxidized) HDL but not normal HDL reduced the ability of HIV-1-specific CTLs to suppress viral replication. Thus, oxidized HDL may contribute to viral persistence in vivo through dysfunction of cellular antiviral immunity. Since HIV-1 infected subjects have dysfunctional HDL compared to uninfected subjects, further studies are warranted to evaluate whether modified lipoproteins may contribute to immune activation in HIV-1 infection.